Savara (SVRA)

• Market cap: $1.12B
• 1 day: 2.22%
• 5 days: -4.5%
• 1 month: -2.13%
• 3 months: 29.27%
• 6 months: 114.79%
• Year to date: -2.13%
• 1 year: 97.14%
• 5 years: 260.78%
• 10 years: -80.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Employees: 59